SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

Teva’s BXCL501 Is Under FDA Review for At-Home Use

The FDA is reviewing BXCL501, a dexmedetomidine sublingual film, for first-ever at-home use to treat agitation associated with schizophrenia or bipolar I or II disorder in adults.

TEVA

Related stories